Patents by Inventor Glay Chinea Santiago
Glay Chinea Santiago has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230405106Abstract: The present invention provides a chimeric protein that has a modular structure and comprises a receptor binding domain (RBD) from the spike protein (S) of coronaviruses, a segment able to bind the core antigen from the Hepatitis B Virus (HBcAg), a segment including six consecutive histidine residues (HHHHHH), and two spacer segments. In this chimeric protein the aforementioned segments are arranged in a specific order, and the protein is able to form hybrid nanoparticles with HBcAg. The chimeric protein is part of vaccine compositions used for the prevention of coronavirus infections. Therefore, the invention discloses a method for the prevention of coronavirus infections, whereby a vaccine composition comprising said chimeric protein is administered.Type: ApplicationFiled: November 3, 2021Publication date: December 21, 2023Inventors: Glay CHINEA SANTIAGO, Alejandro Miguel MARTÍN DUNN, Diamilé GONZÁLEZ ROCHE, Miladys LIMONTA FERNÁNDEZ, Enrique IGLESIAS PÉREZ, Mónica BEQUET ROMERO, Héctor SANTANA MILIAN, Gabriel J. MARQUEZ PERERA, Alexis MUSACCHIO LASA, Ania CABRALES RICO, Gerardo Enrique GUILLEN NIETO, Marta AYALA ÁVILA, Eulogio PIMENTEL VAZQUEZ, Gertrudis ROJAS DORANTES, Vivian HUERTA GALINDO
-
Patent number: 9896482Abstract: The present invention discloses structurally constrained synthetic peptides that have been optimized for the formation of a beta hairpin structure. Said peptides are able to inhibit or attenuate Dengue virus (DENV) infections. The invention also discloses pharmaceutical compositions containing these synthetic peptides, which are useful for the prevention and/or treatment of DENV-caused infections. Likewise, the invention disclosed a method for treating infections caused by this virus.Type: GrantFiled: February 26, 2015Date of Patent: February 20, 2018Assignee: Centro de Ingenieria Genética y BiotechnologiaInventors: Glay Chinea Santiago, Vivian Huerta Galindo, Alejandro Miguel Martín Dunn, Hilda Elisa Garay Pérez, Osvaldo Reyes Acosta, Viviana Falcón Cama, Dianne Pupo Gómez, Alexis Yero Díaz, Gabriel Jesús Márquez Perera, Mónica Sarría Núñez, Osmany Guirola Cruz, Rocío Garateix Suárez, Karen Alvarez Pérez, Sonia González Blanco, Mariela Vázquez Castillo, Luis Javier González López
-
Publication number: 20170152290Abstract: The present invention discloses structurally constrained synthetic peptides that have been optimized for the formation of a beta hairpin structure. Said peptides are able to inhibit or attenuate Dengue virus (DENV) infections. The invention also discloses pharmaceutical compositions containing these synthetic peptides, which are useful for the prevention and/or treatment of DENV-caused infections. Likewise, the invention disclosed a method for treating infections caused by this virus.Type: ApplicationFiled: February 26, 2015Publication date: June 1, 2017Inventors: Glay CHINEA SANTIAGO, Vivian HUERTA GALINDO, Alejandro Miguel MARTÍN DUNN, Hilda Elisa GARAY PÉREZ, Osvaldo REYES ACOSTA, Viviana FALCÓN CAMA, Dianne PUPO GÓMEZ, Alexis YERO DÍAZ, Gabriel Jesús MÁRQUEZ PERERA, Mónica SARRÍA NÚÑEZ, Osmany GUIROLA CRUZ, Rocío GARATEIX SUÁREZ, Karen ALVAREZ PÉREZ, Sonia GONZÁLEZ BLANCO, Mariela VÁZQUEZ CASTILLO, Luis Javier GONZÁLEZ LÓPEZ
-
Patent number: 9375459Abstract: The present invention comprises cyclic peptides bearing antitumor and antiangiogenic properties, as well as their corresponding pharmaceutically-suitable salts and also pharmaceutical compositions containing it. These cyclic peptides are used to prepare medicines for human and/or veterinary therapeutics, and additionally in diagnosis. These compounds can be used to detect, monitor and/or control a range of cellular proliferation-related disorders, such as oncological diseases and undesired angiogenesis. Moreover, they can be included as part of controlled release systems, and used more precisely in the field of nanobiotechnology, either because of their self-assembly capacity or as part of other systems.Type: GrantFiled: March 21, 2012Date of Patent: June 28, 2016Assignee: CENTRO DE INGENIERIA GENETICA BIOTECNOLGIAInventors: María del Carmen Abrahantes Pérez, Glay Chinea Santiago, Eduardo Martínez Diaz, Hilda Elisa Garay Pérez, Osvaldo Reyes Acosta, Ernesto Lopez Mola, Cruz Matilde Lopez Abad, Sonia Gonzalez Blanco
-
Patent number: 8722742Abstract: Use of chemical compounds obtained in silico for the preparation of pharmaceutical compositions to attenuate or inhibit Dengue virus infection. Particularly, through the interference or the modulation of several stages of viral replication cycle related with the entry of virus into host cells and the assembly of mature progeny virions. The invention also comprises the use of such pharmaceutical compositions for prophylactic and/or therapeutic treatment of infection caused by all four serotypes of Dengue virus and other flaviviruses.Type: GrantFiled: February 27, 2009Date of Patent: May 13, 2014Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Yuliet Mazola Reyes, Glay Chinea Santiago, Osmany Guirola Cruz, Roberto Vera Alvarez, Vivian Huerta Galindo, Noralvis Fleitas Salazar, Alexis Musacchio Lasa
-
Publication number: 20140112976Abstract: The present invention comprises cyclic peptides bearing antitumor and antiangiogenic properties, as well as their corresponding pharmaceutically-suitable salts and also pharmaceutical compositions containing it. These cyclic peptides are used to prepare medicines for human and/or veterinary therapeutics, and additionally in diagnosis. These compounds can be used to detect, monitor and/or control a range of cellular proliferation-related disorders, such as oncological diseases and undesired angiogenesis. Moreover, they can be included as part of controlled release systems, and used more precisely in the field of nanobiotechnology, either because of their self-assembly capacity or as part of other systems.Type: ApplicationFiled: March 21, 2012Publication date: April 24, 2014Applicant: CENTRO DE INGENIERIA GENETICA BIOTECNOLOGIAInventors: María del Carmen Abrahantes Pérez, Glay Chinea Santiago, Eduardo Martínez Díaz, Hilda Elisa Garay Perez, Osvaldo Reyes Acosta, Ernesto Lopez Mola, Cruz Matilde Lopez Abad, Sonia Gonzalez Blanco
-
Patent number: 8674063Abstract: The present invention is relative to chimerical peptides, whose primary structure holds at least one segment which inhibits the activation of the NS3 protease of a virus from the Flaviviridae family, they also contain a cell penetrating segment and they are capable of inhibiting or attenuate the viral infection. This invention is also relative to pharmaceutical compounds which contain these chimerical peptides for the prevention and/or treatment of the infection caused by a virus of the Flaviviridae family.Type: GrantFiled: October 30, 2007Date of Patent: March 18, 2014Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Glay Chinea Santiago, Vivian Huerta Galindo, Alejandro Miguel Martin Dunn, Noralvis Fleitas Salazar, Osmany Guirola Cruz, Patricia Gabriela Toledo Mayora, Mónica Sarría Núñez, Alexis Musacchio Lasa, Olvaldo Reyes Acosta, Hilda Elisa Garay Pérez, Anìa Cabrales Rico
-
Patent number: 8420311Abstract: The present invention is related to a method for blocking the infection of cells by dengue virus, based on interfering the direct interaction of the viral envelope protein with a cellular receptor or its indirect interaction with said cellular receptor through a carrier protein, as well as related uses; wherein said cellular receptor is the alpha-2 macroglobulin receptor, also known as the low density receptor-related protein or as CD91, and said carrier protein is human alpha-2 macroglobulin.Type: GrantFiled: April 26, 2007Date of Patent: April 16, 2013Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Vivian Huerta Galindo, Glay Chinea Santiago, Noralvis Fleitas Salazar, Alejandro Miguel Martin Dunn, Monica Sarria Nunez, Osmany Guirola Cruz, Patricia Gabriela Toledo Mayora, Aniel Sanchez Puente, Vladimir Armando Besada Perez, Osvaldo Reyes Acosta, Hilda Elisa Garay Perez, Ania Cabrales Rico, Alexis Musacchio Lasa, Gabriel Ramon Padron Palomares, Luis Javier Gonzalez Lopez
-
Patent number: 8367620Abstract: Peptidic chemical compounds obtained by in silico molecular modelling, having a structure that enables them to perform the same functions of peptidic growth hormone secretagogues. The invention also comprises the preparations containing such compounds and the use in medicines, food additives, nutritional supplements or other formulations of human or animal use.Type: GrantFiled: February 28, 2007Date of Patent: February 5, 2013Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Rolando Eduardo Rodriguez Fernandez, Ania De La Nuez Veulens, Mario Pablo Estrada Garcia, Rebeca Martinez Rodriguez, Glay Chinea Santiago, Osvaldo Reyes Acosta, Julio Raul Fernandez Masso, Diana Garcia del Barco Herrera, Jorge Amador Berlanga Acosta, Alexis Musacchio Lasa
-
Patent number: 8105606Abstract: The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from Neisseria meningitidis with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.Type: GrantFiled: April 26, 2011Date of Patent: January 31, 2012Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Lisset Hermida Cruz, Rayner Rodriguez Diaz, Laura Lazo Vazquez, Aida Zulueta Morales, Carlos Lopez Abarrategui, Iris Valdes Prado, Ricardo de la C. Silva Rodriguez, Glay Chinea Santiago, Gerardo Enrique Guillen Nieto, Maria Guadalupe Guzman Tirado, Beatriz de la Caridad Sierra Vazquez, Raul Rafael Espinosa Perez
-
Publication number: 20110212105Abstract: The present invention is related to a method for blocking the infection of cells by dengue virus, based on interfering the direct interaction of the viral envelope protein with a cellular receptor or its indirect interaction with said cellular receptor through a carrier protein, as well as related uses; wherein said cellular receptor is the alpha-2 macroglobulin receptor, also known as the low density receptor-related protein or as CD91, and said carrier protein is human alpha-2 macroglobulin.Type: ApplicationFiled: April 26, 2007Publication date: September 1, 2011Inventors: Vivian Huerta Galindo, Glay Chinea Santiago, Noralvis Fleitas Salazar, Alejandro Miguel Martín Dunn, Mónica Sarría Núñez, Osmany Guirola Cruz, Patricia Gabriela Toledo Mayora, Aniel Sánchez Puente, Vladimir Armando Besada Pérez, Osvaldo Reyes Acosta, Hilda Elisa Garay Pérez, Ania Cabrales Rico, Alexis Musacchio Lasa, Gabriel Ramón Padrón Palomares, Luis Javier González López
-
Publication number: 20110200628Abstract: The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from Neisseria meningitidis with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.Type: ApplicationFiled: April 26, 2011Publication date: August 18, 2011Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Lisset Hermida Cruz, Rayner Rodriguez Diaz, Laura Lazo Vazquez, Aida Zulueta Morales, Carlos Lopez Abarrategui, Iris Valdes Prado, Ricardo de la C. Silva Rodriguez, Glay Chinea Santiago, Gerardo Enrique Guillen Nieto, Maria Guadalupe Guzman Tirado, Beatriz de la Caridad Sierra Vazquez, Raul Rafael Espinosa Perez
-
Patent number: 7947281Abstract: The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from Neisseria meningitidis with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.Type: GrantFiled: June 12, 2009Date of Patent: May 24, 2011Assignee: Centro de Ingenieria Genetica y BiotechnologiaInventors: Lisset Hermida Cruz, Rayner Rodriguez Diaz, Laura Lazo Vazquez, Aida Zulueta Morales, Carlos Lopez Abarrategui, Iris Valdes Prado, Richardo de la C. Silva Rodriguez, Glay Chinea Santiago, Gerardo Enrique Guillen Nieto, Maria Guadalupe Guzman Tirado, Beatriz de la Caridad Sierra Vazquez, Raul Rafael Espinosa Perez
-
Publication number: 20110065686Abstract: Use of chemical compounds obtained in silico for the preparation of pharmaceutical compositions to attenuate or inhibit Dengue virus infection. Particularly, through the interference or the modulation of several stages of viral replication cycle related with the entry of virus into host cells and the assembly of mature progeny virions. The invention also comprises the use of such pharmaceutical compositions for prophylactic and/or therapeutic treatment of infection caused by all four serotypes of Dengue virus and other flaviviruses.Type: ApplicationFiled: February 27, 2009Publication date: March 17, 2011Inventors: Yuliet Mazola Reyes, Glay Chinea Santiago, Osmany Guirola Cruz, Roberto Vera Alvarez, Vivian Huerta Galindo, Noralvis Fleitas Salazar, Alexis Musacchio Lasa
-
Publication number: 20100273702Abstract: The present invention is relative to chimerical peptides, whose primary structure holds at least one segment which inhibits the activation of the NS3 protease of a virus from the Flaviviridae family, they also contain a cell penetrating segment and they are capable of inhibiting or attenuate the viral infection. This invention is also relative to pharmaceutical compounds which contain these chimerical peptides for the prevention and/or treatment of the infection caused by a virus of the Flaviviridae family.Type: ApplicationFiled: October 30, 2007Publication date: October 28, 2010Inventors: Glay Chinea Santiago, Vivian Juerta Galindo, Alejandro Miguel Martin Dunn, Noralvis Fleitas Salazar, Osmany Guirola Cruz, Patricia Gabriela Toledo Mayora, Mónica Srria Nüñez, Alexis Musacchio Lasa, Osvaldo Reyes Acosta, Hilda Elisa Garay Pérez, Ania Cabrales Rico
-
Publication number: 20100151566Abstract: The present invention deals with recombinant polypeptide molecules related to antibodies, that specifically recognize the human Vascular Endothelial Growth Factor A (VEGF-A), and interfere with its in vitro stimulatory effects and pro-angiogenic activity in vivo. These recombinant polypeptide molecules affect proliferation of human endothelial cells in vitro, subcutaneous angiogenesis in mice induced by Matrigel pellets that contain VEGF-A and the growth of human tumors transplanted in nude athymic mice. Several of these moleculas prevent choroideal neovascularization in a non human primate experimental model.Type: ApplicationFiled: October 30, 2007Publication date: June 17, 2010Inventors: Humberto Lamdan Ordás, Jorge Víctor Gavilondo Cowley, Marta Ayala Avila, Gertrudis Rojas Dorantes, Yanelys Morera Díaz, Osmany Guirola Cruz, Glay Chinea Santiago, Nelson Francisco Santiago Vispo
-
Publication number: 20100055118Abstract: Peptidic chemical compounds obtained by in silico molecular modelling, having a structure that enables them to perform the same functions of peptidic growth hormone secretagogues. The invention also comprises the preparations containing such compounds and the use in medicines, food additives, nutritional supplements or other formulations of human or animal use.Type: ApplicationFiled: February 28, 2007Publication date: March 4, 2010Applicant: CENTRO DE INGENÍERA GENÉTICA Y BIOTECNOLOGÍAInventors: Rolando Eduardo Rodriguez Fernandez, Ania De La Nuez Veulens, Mario Pablo Estrada Garcia, Rebeca Martinez Rodriguez, Glay Chinea Santiago, Osvaldo Reyes Acosta, Julio Raul Fernandez Masso, Diana Garcia Del Barco Herrera, Jorge Amador Berlanga Acosta, Alexis Musacchio Lasa
-
Publication number: 20090312190Abstract: The present invention is related to the field of the pharmaceutical industry, and describes a conserved area on the surface of the E protein that can be used for the development of wide-spectrum antiviral molecules to be employed in the prophylaxis and/or treatment of infections due to Dengue Virus serotypes 1-4 and other flaviviruses. The invention also covers chimeric proteins to be used as vaccines or as a prophylactic or therapeutic treatment against the four serotypes of Dengue Virus and other flaviviruses.Type: ApplicationFiled: November 21, 2006Publication date: December 17, 2009Applicant: CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍAInventors: Glay Chinea Santiago, Vivian Huerta Galindo, Alejandro Miguel Martin Dunn, Jorge Victor Gavilondo Cowley, Noralvis Fleitas Salazar, Osmany Guirola Cruz, Jeovanis Gil Valdés, Aída Zulueta Morales, Lisset Hermida Cruz, Marta Ayala Avila, Diamilé Gonzáles Roche, Rolando Paez Meireles, Patricia Gabriela Toledo Mayora, Mónica Sarria Núnez, Alexis Musacchio Lasa, Yuliet Mazola Reyes
-
Publication number: 20090274718Abstract: The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from Neisseria meningitidis with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.Type: ApplicationFiled: June 12, 2009Publication date: November 5, 2009Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Lisset Hermida Cruz, Rayner Rodriguez Diaz, Laura Lazo Vazquez, Aida Zulueta Morales, Carlos Lopez Abarrategui, Iris Valdes Prado, Ricardo de la C. Silva Rodriguez, Glay Chinea Santiago, Gerardo Enrique Guillen Nieto, Maria Guadalupe Guzman Tirado, Beatriz de la Caridad Sierra Vazquez, Raul Rafael Espinosa Perez
-
Patent number: 7566457Abstract: The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonspecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from Neisseria meningitidis with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.Type: GrantFiled: February 13, 2007Date of Patent: July 28, 2009Assignee: Centro de Ingeniera Genetica y BiotecnologiaInventors: Lisset Hermida Cruz, Rayner Rodriguez Diaz, Laura Lazo Vazquez, Aida Zulueta Morales, Carlos Lopez Abarrategui, Iris Valdes Prado, Ricardo de la C. Silva Rodriguez, Glay Chinea Santiago, Gerardo Enrique Guillen Nieto, Maria Guadalupe Guzman Tirado, Beatriz de la Caridad Sierra Vazquez, Raul Rafael Espinosa Perez